

Seminarios de Patólogos Latinoamericanos

Pablo Goyenaga

F. Nogales



Ficha de Identificación:

- Masculino de 47 años


1993

- Antecedente quirúrgico de orquidectomía + Quimioterapia (VP, CDDP y BLM)
 - Tumor no seminomatoso
 - Teratoma Maduro
- El paciente con seguimiento irregular

- **2010** (consulta por dolor lumbar izquierdo)
 - US y TAC: Masa renal izquierda de 10x8.5x8 cm
 - Infiltración de uréter, psoas y arteria iliaca rodeando la aorta
 - Metástasis a pulmón y cuerpo vertebral lumbar
 - Marcadores tumorales: aumento de la **hCG**
- Nefrectomía Izquierda


ABDOMEN
NO C
Series 2
Image 25/45

10/08/2010




W: 399 L: 40






- Carcinoma urotelial sólido de alto grado
 - Hidronefrosis antigua
 - Marcada atrofia del parénquima renal



hCG

α -Inhibina

Lact Plac H




- Carcinoma urotelial sólido de alto grado sobre una hidronefrosis antigua con atrofia del parénquima
 - Diferenciación trofoblástica:
 - Sincitiotrofoblasto (HCG +)

Placental Proteins in High-Grade Urothelial Neoplasms

An Immunohistochemical Study of Human Chorionic Gonadotropin, Human Placental Lactogen, and Pregnancy-Specific Beta-1-Glycoprotein


ELIAS CAMPO, MD,* FERRAN ALGABA, MD,† ANTONIO PALACIN, MD,* RAMON GERMA, MD,‡
FRANCISCO JAVIER SOLE-BALCELLS, MD,† AND ANTONIO CARDESA, MD*



SALL4

Glypican3

CDX2



- Carcinoma urotelial sólido de alto grado sobre una hidronefrosis antigua con atrofia del parénquima
 - Diferenciación trofoblástica:
 - Sincitiotrofoblasto (HCG +)
 - Diferenciación endodérmica primitiva (yolk sac)
 - Tipo glandular

Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of *Pou5f1*

Jinxiu Zhang^{1,8}, Wai-Leong Tam^{1,2,8}, Guo Qing Tong^{1,8}, Qiang Wu³, Hsiao-Yun Chan¹, Boon-Seng Soh¹, Yuefei Lou¹, Jianchang Yang⁴, Yupo Ma⁴, Li Chai⁵, Huck-Hui Ng^{3,6}, Thomas Lufkin^{1,6}, Paul Robson^{1,6} and Bing Lim^{1,7,9}

OPEN ACCESS Freely available online



A Novel SALL4/OCT4 Transcriptional Feedback Network for Pluripotency of Embryonic Stem Cells

Jianchang Yang¹, Chong Gao², Li Chai^{2*}, Yupo Ma^{1*}

1 Division of Laboratory Medicine, Nevada Cancer Institute, Las Vegas, Nevada, United States of America, **2** The Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

MOLECULAR AND CELLULAR BIOLOGY, Nov. 2010, p. 5364–5380

0270-7306/10/\$12.00 doi:10.1128/MCB.00419-10

Copyright © 2010, American Society for Microbiology. All Rights Reserved.

Vol. 30, No. 22

Differential Roles of Sall4 Isoforms in Embryonic Stem Cell Pluripotency[†]

Sridhar Rao,^{1,2} Shao Zhen,^{1,2} Sergei Roumiantsev,^{2,3} Lindsay T. McDonald,^{1,4}
Guo-Cheng Yuan,¹ and Stuart H. Orkin^{1,2,4,5*}

Dana Farber Cancer Institute, Departments of Pediatric Oncology and Computational Biology,¹ Children's Hospital, Division of Pediatric Hematology-Oncology,² Massachusetts General Hospital for Children, Division of Newborn Medicine,³ Howard Hughes Medical Institute,⁴ and Harvard Stem Cell Institute,⁵ Boston, Massachusetts 02115

Received 10 April 2010/Returned for modification 29 May 2010/Accepted 28 August 2010




Correspondence

Glypican 3 is a sensitive, but not a specific, marker for the diagnosis of yolk sac tumours

Response to Zynger *et al.* Glypican 3 has a higher sensitivity than alpha-fetoprotein for testicular and ovarian yolk sac tumours: immunohistochemical investigation with analysis of histological growth patterns. *Histopathology* 2010; 56: 750–757

Ovidiu Preda
Alina Nicolae¹
José Aneiros-Fernández¹
Angela Borda
Francisco F Nogales¹

Department of Histology, Medical University of Targu Mures, Romania, and ¹Department of Pathology, San Cecilio University Hospital, Granada, Spain



	IGCNU	Seminomas	Embryonal carcinomas	Yolk sac tumours	Choriocarcinomas	Teratomas	Spermatocytic seminomas
SALL4	100%	100%	100%	100%	0%	50%	100%
OCT3/4	100%	100%	100%	0%	0%	0%	0%
SOX2	0%	0%	100%	0%	0%	15%#	0%
GLP3	0%	0%	17%	100%	100% †	60%	50%
D2-40	100%	100%	100%	8%	0%	40%	0%
PLAP	100%	95,33%	97,56%	4%	25% †	35%	0%
CD30	0%	0%	90,24%	0%	0%	0%	0%
AFP	0%	0%	0%	88%	0%	10%	0%

- La variante glandular del YST es difícil de reconocer cuando se asocia con tumores somáticos.
- La diferenciación embrionaria originada de una neoplasia urotelial es poco común.
- El epitelio vacuolado distintivo y un inmunofenotipo característico, discrimina el YST glandular de otras proliferaciones glandulares primarias o secundarias
- Su patogenia podría estar relacionada con las células madre pluripotentes malignas presentes en el tumor somático.